Truist Securities Maintains Buy on Viking Therapeutics, Maintains $120 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee maintains a Buy rating on Viking Therapeutics (NASDAQ:VKTX) with a $120 price target.
June 17, 2024 | 3:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Joon Lee maintains a Buy rating on Viking Therapeutics with a $120 price target, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a high price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100